6 assets in Syndromic Agammaglobulinemia

Therapeutic assets addressing Syndromic Agammaglobulinemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Xembify Syndromic Agammaglobulinemia	Grifols Therapeutics LLC	P3	B (60)
Amoxicillin Syndromic Agammaglobulinemia	Monash University	P2/3	B (57)
Ciprofloxacin Syndromic Agammaglobulinemia	Monash University	P2/3	B (57)
Clavulanic Acid Syndromic Agammaglobulinemia	Monash University	P2/3	B (57)
Human Immunoglobulins Syndromic Agammaglobulinemia	Monash University	P2/3	B (57)
Igpro20 Syndromic Agammaglobulinemia	Memorial Sloan Kettering Cancer Center	P2	CCC (53)